Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer

NCT07379476 | Recruiting Phase 2

• 1 other identifier: LUN126
• Study Type: interventional
• Target: 64
• Locations: 1 country
• Sites: 1

Brief Summary

This is an open-label, multicentre, randomized phase II clinical trial. Patients with stage IV (AJCC 9th edition) non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion or exon 21 L858R mutation, who had less than or equal to 3 active oligoresidual cancer sites amenable to local ablative therapy (LAT) (as determined by physician) after 3-6 months of firstline osimertinib treatment, are eligible. Subjects will be randomized 1:1 to osimertinib with or without LAT.

Conditions

Lung Cancer (NSCLC)

Outcome Measures

Primary Outcomes (1)

• 18 month progression-free survival rate (PFS) in per-protocol population as determined by investigator.

  up to 2 years

Secondary Outcomes (4)

• Overall survival (OS)

  2 years

• Safety and tolerability reflected by number of participants with treatment related adverse events as assessed by CTCAE v5.0, number of participants with SAE

  2 years

• Time to treatment failure (TTF), defined as the time period between osimertinib initiation and cessation or death

  2 years

• Site of tumour progression at disease progression

  2 years

Study Arms (2)

Radiotherapy arm

EXPERIMENTAL

* Continue osimertinib as per standard of care (40mg or 80mg daily). * Undergo radiotherapy to 1-3 disease sites as determined by the investigator.

Radiation: Local ablative therapy

Control arm

ACTIVE COMPARATOR

Continue osimertinib as per standard of care (40mg or 80mg daily)

Drug: Osimertinib alone

Interventions

Local ablative therapy RADIATION

Local ablative therapy (LAT) will be given in the form of stereotactic body radiotherapy (SBRT) or hypofractionated radiotherapy. LAT should be started within 90 days from the screening PET-CT scan.

Radiotherapy arm

Osimertinib alone DRUG

Continue osimertinib as per standard of care (40mg or 80mg daily)

Control arm

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• years of age or older and able to understand and give written informed consent
• Pathologically proven non-small cell lung cancer
• Positive for EGFR exon 19 deletion or EGFR exon 21 L858R mutation (either by tissue or plasma testing)
• Stage IV disease
• Receive first line osimertinib monotherapy for stage IV disease
• Undergo a PET-CT scan after 12-24 weeks of initiation of osimertinib treatment, with no evidence of disease progression, and less than or equal to 3 active disease sites (including primary tumour) amenable to local ablative therapy, as determined by investigator
• At least one brain imaging (CT Brain or MRI Brain with contrast, preferably MRI Brain), either at time of diagnosis or while on osimertinib treatment but before randomization, to document CNS status for stratification. Patients with asymptomatic CNS metastases are eligible. For patients with brain metastases diagnosed at baseline, follow up brain imaging is recommended before randomization.
• Patients with history of palliative radiotherapy are eligible
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• Adequate haematological values: haemoglobin ≥9.0g/dL, absolute neutreophil count ≥1.0 x 109/L, platelet count ≥100 x 109/L
• Adequate hepatic function: bilirubin ≤1.5 x ULN, AST/ALT ≤2.5 x ULN
• Adequate renal function: creatinine clearance ≥30ml/min, according to the formula of Cockcroft-Gault equation
• Willing and able to comply with the requirements and restrictions in this protocol

You may not qualify if:

• Previous or concomitant malignancy within 5 years prior registration with the exception of adequately treated localized non-melanoma skin cancer or cervical cancer in situ.
• Mixed SCLC and NSCLC histology
• Positive pregnancy test
• Contraindication to radiotherapy
• Any serious underlying medical, psychiatric, psychological, familial condition that in the judgement of the investigator, that may interfere with planned staging, treatment and follow up, affect patient compliance, or place the patient at high risk from treatment related complications

Sponsors & Collaborators

• Chinese University of Hong Kong: lead

Study Sites (1)

Department of Clinical Oncology, Prince of Wales Hospital

Hong Kong, Hong Kong

RECRUITING

MeSH Terms

Conditions

Lung Neoplasms; Carcinoma, Non-Small-Cell Lung

Interventions

osimertinib

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms

Central Study Contacts

Molly SC LI, MBBS, MRCP

CONTACT

3505 1042; molly@clo.cuhk.edu.hk

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor

Study Record Dates

• First Submitted: December 17, 2025
• First Posted: January 30, 2026
• Study Start: February 11, 2026
• Primary Completion (Estimated): March 3, 2029
• Study Completion (Estimated): March 3, 2030
• Last Updated: February 12, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

HK (1)